9th Aug 2016 11:51
LONDON (Alliance News) - Summit Therapeutics PLC on Tuesday reported positive phase I trial results for a new formulation of its Duchenne Muscular Dystrophy candidate ezutromid, and set out its clinical strategy for the treatment.
The trial data showed that the new formulation showed a greater than six-fold increase in maximum plasma levels in DMD patients, compared to those achieved with its current clinical formulation, with only two fifths of the dose.
"The rigorous development of ezutromid has identified this new F6 formulation that achieved higher ezutromid plasma levels in patients in this trial allowing us to further explore the therapeutic effect of this promising treatment," said Chief Medical Officer of Summit Ralf Rosskamp in a statement.
"Following these encouraging Phase 1 data, we plan to incorporate the F6 formulation of ezutromid into our ongoing Phase 2 trial, PhaseOut DMD. This will allow us to directly compare the safety and efficacy of the F6 and F3 formulations of ezutromid, and help determine which to use in future clinical trials," Rosskamp added.
Shares in Summit Therapeutics were up 7.0% at 104.35 pence Tuesday following the announcement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
SUMM.L